Artwork

Going Anti-Viral에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Going Anti-Viral 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

Episode 12 - New Study on Treatments for Non-Alcoholic Fatty Liver Disease in People With HIV With Dr Jordan Lake Recorded Live from CROI 2024

24:13
 
공유
 

Manage episode 406081910 series 3516544
Going Anti-Viral에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Going Anti-Viral 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Episode 12 - New Study on Treatments for Non-Alcoholic Fatty Liver Disease in People With HIV With Dr Jordan Lake Recorded Live from CROI 2024

In this episode, Dr Michael Saag speaks with Dr Jordan Lake live from the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). They discuss the prevalence of non-alcoholic fatty liver disease (NAFLD) among people with HIV and explore the effectiveness of the GLP-1 receptor agonist semaglutide, commonly used to treat diabetes and aid in weight loss, to treat NAFLD. Future areas of research are considered, including maintenance strategies post-weight loss and a placebo-controlled version of the study.

00:02 Introduction and Welcome

00:44 Discussion on Non-Alcoholic Fatty Liver Disease in People With HIV

01:56 Role of HIV in Non-Alcoholic Fatty Liver Disease

02:43 Understanding the Inflammation and Fat Accumulation in the Liver

04:38 Exploring the Impact of Nucleoside Therapy on Non-Alcoholic Fatty Liver Disease

06:37 Potential Treatments for Non-Alcoholic Fatty Liver Disease

07:35 The Role of Semaglutide in Treating Non-Alcoholic Fatty Liver Disease

13:36 The Importance of Routine Assessment for Non-Alcoholic Fatty Liver Disease

15:37 Exploring New Drugs for Treating Non-Alcoholic Fatty Liver Disease

18:49 The Challenges and Future Directions in Non-Alcoholic Fatty Liver Disease Research

22:25 Conclusion and Closing Remarks

__________________________________________________
Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.
Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.
Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...

  continue reading

26 에피소드

Artwork
icon공유
 
Manage episode 406081910 series 3516544
Going Anti-Viral에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Going Anti-Viral 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Episode 12 - New Study on Treatments for Non-Alcoholic Fatty Liver Disease in People With HIV With Dr Jordan Lake Recorded Live from CROI 2024

In this episode, Dr Michael Saag speaks with Dr Jordan Lake live from the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). They discuss the prevalence of non-alcoholic fatty liver disease (NAFLD) among people with HIV and explore the effectiveness of the GLP-1 receptor agonist semaglutide, commonly used to treat diabetes and aid in weight loss, to treat NAFLD. Future areas of research are considered, including maintenance strategies post-weight loss and a placebo-controlled version of the study.

00:02 Introduction and Welcome

00:44 Discussion on Non-Alcoholic Fatty Liver Disease in People With HIV

01:56 Role of HIV in Non-Alcoholic Fatty Liver Disease

02:43 Understanding the Inflammation and Fat Accumulation in the Liver

04:38 Exploring the Impact of Nucleoside Therapy on Non-Alcoholic Fatty Liver Disease

06:37 Potential Treatments for Non-Alcoholic Fatty Liver Disease

07:35 The Role of Semaglutide in Treating Non-Alcoholic Fatty Liver Disease

13:36 The Importance of Routine Assessment for Non-Alcoholic Fatty Liver Disease

15:37 Exploring New Drugs for Treating Non-Alcoholic Fatty Liver Disease

18:49 The Challenges and Future Directions in Non-Alcoholic Fatty Liver Disease Research

22:25 Conclusion and Closing Remarks

__________________________________________________
Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.
Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.
Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...

  continue reading

26 에피소드

Όλα τα επεισόδια

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드